Rossari Biotech Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹698 Cr +19.1% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
RB

Rossari Biotech Ltd

Q3 FY26Chemicals & Petrochemicals

Rossari Biotech Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹582Cr
+13.5% YoY
−0.7% QoQ
Net profit
₹33Cr
+3.1% YoY
−10.8% QoQ
Margin
12%
−1 pp YoY
0 pp QoQ
Price₹502
Market cap₹2.8K Cr
P/E18.5

The short version

Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26. Earnings growth expected to continue, supported by steady volume growth across business segments.

From Rossari Biotech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26.
  • Domestic demand, especially in textiles, remains soft but export markets like Southeast Asia, MENA, Middle East, and Turkey show promise.
  • Animal Health and Nutrition (AHN) business demonstrated strong growth; expected to maintain average growth with new premix plant coming onstream.
  • Ramp-up of new capacities at Dahej and Unitop to continue, with optimal utilization targeted by FY27, supporting volume growth.
  • New product development and market expansion prioritized, including setting up a manufacturing facility in KSA to enhance supply chain and export reach.

2 more points from Rossari Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ethoxylation capacity expansion at Unitop is on track, with balance capacity expected to come onstream in Q4 FY26.
  • Non-EO based capacities for Unitop, Tristar, and Rossari are planned for the next year, phased for Q3 and Q4 FY26.
  • The Saudi Arabia greenfield specialty chemicals manufacturing facility has received in-principle Board approval; initial equity infusion of $8 million approved for evaluation and groundwork, with the total capex to be determined post-assessment and formal Board approval.

2 more points from Rossari Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant points related to demand and order outlook include: - Exports have been growing strongly and contributed about 30% of turnover in the 9 months ended FY26. - Domestic demand, especially in textiles, has been soft but showed some signs of recovery in Q3 FY26. - The company is adding customers in new geographies like Turkey, Uzbekistan, Morocco, Southeast Asia, and others, indicating an expanding order pipeline. - Discussions and in-principle approvals for a new greenfield manufacturing facility in Saudi Arabia are underway, aimed at strategically catering to regional and export demand. - Ramp-up of new capacities at Dahej and Unitop is expected to progressively contribute to order fulfillment over the next 2 years.

2 more points from Rossari Biotech Ltd's call on order book

Create a free account to keep reading this call

Rossari Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Rossari Biotech Ltd Q3 FY26 results — key figures

Rossari Biotech Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue582513+13.5%586-0.7%
Operating profit (EBITDA)6965+6.2%72-4.2%
Operating margin12%13%-1 pp12%0 pp
Profit before tax4342+2.4%50-14%
Net profit (PAT)3332+3.1%37-10.8%
EPS (₹)5.925.73+3.3%6.66-11.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Neochem Bio (Q3 FY26)

    Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and

  • Thirumalai Chemicals (Q3 FY26)

    Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran

  • IVP (Q3 FY26)

    Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector

  • Gujarat Alkalies (Q3 FY26)

    3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Rossari Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Rossari Biotech Ltd Q3 FY26 results?

Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26. Earnings growth expected to continue, supported by steady volume growth across business segments.

What is Rossari Biotech Ltd share price analysis?

Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech Ltd planning capital expenditure?

Ethoxylation capacity expansion at Unitop is on track, with balance capacity expected to come onstream in Q4 FY26.

Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.